Bausch + Lomb Stock Price, News & Analysis (NYSE:BLCO) $15.64 +0.30 (+1.96%) (As of 12/8/2023 ET) Add Compare Share Share Today's Range$15.21▼$15.6950-Day Range$14.87▼$17.5752-Week Range$14.37▼$21.95Volume1.19 million shsAverage Volume425,743 shsMarket Capitalization$5.49 billionP/E RatioN/ADividend YieldN/APrice Target$20.10 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial Media Bausch + Lomb MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside28.5% Upside$20.10 Price TargetShort InterestBearish9.97% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.26Based on 6 Articles This WeekInsider TradingN/AProj. Earnings Growth-1.54%From $0.65 to $0.64 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.42 out of 5 starsMedical Sector887th out of 954 stocksMedical Instruments & Supplies Industry10th out of 10 stocks 3.3 Analyst's Opinion Consensus RatingBausch + Lomb has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 4 buy ratings, 4 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $20.10, Bausch + Lomb has a forecasted upside of 28.5% from its current price of $15.64.Amount of Analyst CoverageBausch + Lomb has only been the subject of 4 research reports in the past 90 days. Previous Next 0.0 Short Interest Percentage of Shares Shorted9.97% of the float of Bausch + Lomb has been sold short.Short Interest Ratio / Days to CoverBausch + Lomb has a short interest ratio ("days to cover") of 10, which indicates bearish sentiment.Change versus previous monthShort interest in Bausch + Lomb has recently increased by 10.03%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldBausch + Lomb does not currently pay a dividend.Dividend GrowthBausch + Lomb does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for BLCO. Previous Next 1.8 News and Social Media Coverage News SentimentBausch + Lomb has a news sentiment score of 0.26. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.51 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Bausch + Lomb this week, compared to 3 articles on an average week.Search InterestOnly 3 people have searched for BLCO on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Bausch + Lomb to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Bausch + Lomb insiders have not sold or bought any company stock.Percentage Held by InstitutionsOnly 12.45% of the stock of Bausch + Lomb is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Bausch + Lomb are expected to decrease by -1.54% in the coming year, from $0.65 to $0.64 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Bausch + Lomb is -26.51, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Bausch + Lomb is -26.51, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Growth RatioBausch + Lomb has a PEG Ratio of 11.08. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioBausch + Lomb has a P/B Ratio of 0.77. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Bausch + Lomb Stock (NYSE:BLCO)Bausch + Lomb Corporation operates as an eye health company worldwide. It operates through three segments: Vision Care, Ophthalmic Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products for therapeutic use, over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions comprising eye allergies, conjunctivitis, dry eye, and redness relief. The Ophthalmic Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment of eye conditions, such as glaucoma, eye inflammation, ocular hypertension, dry eyes, and retinal diseases. The Surgical segment provides medical device equipment, consumables, and technologies for the treatment of corneal, cataracts, and vitreous and retinal eye conditions; and intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices. Bausch + Lomb Corporation was founded in 1853 and is headquartered in Vaughan, Canada. Bausch + Lomb Corporation is a subsidiary of Bausch Health Companies Inc.Read More BLCO Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BLCO Stock News HeadlinesDecember 5, 2023 | americanbankingnews.comBausch + Lomb (NYSE:BLCO) Given New $16.00 Price Target at Morgan StanleyDecember 2, 2023 | americanbankingnews.comBausch + Lomb Co. (NYSE:BLCO) Receives Average Rating of "Moderate Buy" from AnalystsDecember 8, 2023 | DTI Trader (Ad)All the trading advice you’ve ever received boils down to thisAll the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.November 29, 2023 | americanbankingnews.comBausch + Lomb (NYSE:BLCO) Price Target Cut to $17.00 by Analysts at BarclaysNovember 28, 2023 | finance.yahoo.comBausch + Lomb CEO Brent Saunders Pays $35.35 Million for Cher’s Former Miami Beach HomeNovember 15, 2023 | finance.yahoo.comBausch + Lomb Reports More Than 76 Million Units of Contact Lenses, Lens Care and Eye Care Materials Collected Through ONE By ONE and Biotrue® Eye Care Recycling ProgramsNovember 8, 2023 | seekingalpha.comBausch + Lomb: Not A Good Time To Buy (Rating Downgrade)November 7, 2023 | morningstar.comBausch & Lomb Corp BLCODecember 8, 2023 | Autonomix (Ad)[Investor Alert] Potential Breakthrough Medical Tech Investment OpportunityAutonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.comNovember 3, 2023 | markets.businessinsider.comBausch + Lomb Corporation: Strong Q3 Performance and Promising Investments Justify Buy Rating Despite ChallengesNovember 1, 2023 | finance.yahoo.comBausch + Lomb (BLCO) Reports Q3 Earnings: What Key Metrics Have to SayNovember 1, 2023 | markets.businessinsider.comBausch + Lomb Q3 Adj. Profit Declines; Revenues Up 8% On Constant Currency BasisNovember 1, 2023 | finance.yahoo.comBausch + Lomb Announces Third-Quarter 2023 Results and Raises Full-Year 2023 GuidanceNovember 1, 2023 | finance.yahoo.comBausch & Lomb Corp (BLCO) Reports Q3 2023 Earnings and Raises Full-Year GuidanceOctober 26, 2023 | markets.businessinsider.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: CareMax (CMAX), Bausch + Lomb Corporation (BLCO) and Arcus Biosciences (RCUS)October 26, 2023 | finance.yahoo.comBausch + Lomb Will Present New Scientific Data and Analyses at American Academy of Ophthalmology Annual MeetingOctober 25, 2023 | finance.yahoo.comBausch + Lomb (BLCO) Expected to Beat Earnings Estimates: Can the Stock Move Higher?October 17, 2023 | markets.businessinsider.comBausch + Lomb’s Promising Future: A Buy Recommendation Based on New Drug Launch and Potential SynergiesOctober 16, 2023 | finance.yahoo.comBausch + Lomb Will Release Third-Quarter 2023 Financial Results on November 1October 14, 2023 | msn.comMorgan Stanley Maintains Bausch + Lomb (BLCO) Equal-Weight RecommendationOctober 13, 2023 | markets.businessinsider.comHold Rating on Bausch + Lomb Amidst Anticipated Transitional Year and Competitive DynamicsOctober 6, 2023 | markets.businessinsider.comPromising Growth Potential for Bausch + Lomb: Impact of XIIDRA Acquisition and MIEBO LaunchOctober 4, 2023 | msn.comEvercore ISI Group Reiterates Bausch + Lomb (BLCO) Outperform RecommendationOctober 4, 2023 | finance.yahoo.comBausch + Lomb Will Present New Scientific Data and Analyses at American Academy of Optometry Annual MeetingOctober 3, 2023 | markets.businessinsider.com6 Analysts Have This to Say About Bausch & LombSeptember 26, 2023 | finance.yahoo.comBausch + Lomb Launches LUMIFY EYE ILLUMINATIONS™ in the United StatesSeptember 21, 2023 | msn.comBausch Health stock rebounds from Tuesday sell-off, helped by Jefferies upgradeSee More Headlines Receive BLCO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Bausch + Lomb and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/01/2023Today12/08/2023Fiscal Year End12/31/2023Next Earnings (Estimated)2/28/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE Industry Ophthalmic goods Sub-IndustryN/A SectorMedical Current SymbolNYSE:BLCO CUSIPN/A CIK1860742 Webwww.bausch.com Phone905-695-7700FaxN/AEmployees12,900Year FoundedN/APrice Target and Rating Average Stock Price Target$20.10 High Stock Price Target$25.00 Low Stock Price Target$16.00 Potential Upside/Downside+28.5%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)($0.59) Trailing P/E RatioN/A Forward P/E Ratio24.06 P/E Growth11.08Net Income$6 million Net Margins-5.22% Pretax Margin-2.80% Return on Equity3.63% Return on Assets2.18% Debt Debt-to-Equity Ratio0.64 Current Ratio1.78 Quick Ratio1.23 Sales & Book Value Annual Sales$3.97 billion Price / Sales1.38 Cash Flow$2.20 per share Price / Cash Flow7.10 Book Value$20.29 per share Price / Book0.77Miscellaneous Outstanding Shares350,862,000Free FloatN/AMarket Cap$5.49 billion OptionableNot Optionable Beta0.20 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report Key ExecutivesMr. Osama A. Eldessouky (Age 51)Executive VP & CFO Comp: $1.09MDr. Yehia Hashad M.D. (Age 56)Executive VP of Research & Development and Chief Medical officer Comp: $1.09MMr. Brenton L. Saunders J.D. (Age 53)CEO & Chairman Mr. Alan Waterhouse CPFA (Age 63)MBA, Executive VP and Chief Supply Chain & Operations Officer Mr. Frederick J. Munsch (Age 53)Senior VP, Controller & Chief Accounting Officer Mr. A. Robert D. Bailey (Age 60)Executive VP & Chief Legal Officer Mr. Jonathon L. KellermanChief Compliance OfficerT.J. CrawfordChief Communications OfficerDr. Manisha A. Narasimhan Ph.D. (Age 46)Chief Corporate Development & Digital Officer Ms. Asli GevgililiExecutive VP & Chief Human Resources OfficerMore ExecutivesKey CompetitorsSTAAR SurgicalNASDAQ:STAACooper CompaniesNYSE:COOHalozyme TherapeuticsNASDAQ:HALO10x GenomicsNASDAQ:TXGMasimoNASDAQ:MASIView All CompetitorsInstitutional OwnershipWalleye Trading LLCSold 13,800 shares on 11/21/2023Ownership: 0.000%Eminence Capital LPBought 626,431 shares on 11/15/2023Ownership: 1.709%Maple Rock Capital Partners Inc.Bought 333,000 shares on 11/15/2023Ownership: 0.918%Alberta Investment Management CorpBought 380,000 shares on 11/15/2023Ownership: 0.385%Laurion Capital Management LPSold 75,000 shares on 11/15/2023Ownership: 0.295%View All Institutional Transactions BLCO Stock Analysis - Frequently Asked Questions Should I buy or sell Bausch + Lomb stock right now? 8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Bausch + Lomb in the last twelve months. There are currently 4 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" BLCO shares. View BLCO analyst ratings or view top-rated stocks. What is Bausch + Lomb's stock price target for 2024? 8 analysts have issued 1 year target prices for Bausch + Lomb's shares. Their BLCO share price targets range from $16.00 to $25.00. On average, they predict the company's stock price to reach $20.10 in the next twelve months. This suggests a possible upside of 28.5% from the stock's current price. View analysts price targets for BLCO or view top-rated stocks among Wall Street analysts. How have BLCO shares performed in 2023? Bausch + Lomb's stock was trading at $15.51 on January 1st, 2023. Since then, BLCO shares have increased by 0.8% and is now trading at $15.64. View the best growth stocks for 2023 here. Are investors shorting Bausch + Lomb? Bausch + Lomb saw a increase in short interest during the month of November. As of November 15th, there was short interest totaling 3,840,000 shares, an increase of 10.0% from the October 31st total of 3,490,000 shares. Based on an average trading volume of 385,900 shares, the days-to-cover ratio is presently 10.0 days. Currently, 10.0% of the company's stock are sold short. View Bausch + Lomb's Short Interest. When is Bausch + Lomb's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, February 28th 2024. View our BLCO earnings forecast. How were Bausch + Lomb's earnings last quarter? Bausch + Lomb Co. (NYSE:BLCO) issued its quarterly earnings data on Wednesday, November, 1st. The company reported $0.22 earnings per share for the quarter, beating analysts' consensus estimates of $0.18 by $0.04. The firm had revenue of $1.01 billion for the quarter, compared to analyst estimates of $990.68 million. Bausch + Lomb had a negative net margin of 5.22% and a positive trailing twelve-month return on equity of 3.63%. The business's revenue was up 6.9% on a year-over-year basis. During the same period in the prior year, the company earned $0.31 earnings per share. What ETFs hold Bausch + Lomb's stock? ETFs with the largest weight of Bausch + Lomb (NYSE:BLCO) stock in their portfolio include Ballast Small/Mid Cap ETF (MGMT).First Trust US Equity Opportunities ETF (FPX). When did Bausch + Lomb IPO? (BLCO) raised $788 million in an IPO on Friday, May 6th 2022. The company issued 35,000,000 shares at a price of $21.00-$24.00 per share. Who are Bausch + Lomb's major shareholders? Bausch + Lomb's stock is owned by a number of institutional and retail investors. Top institutional investors include Eminence Capital LP (1.71%), Goldentree Asset Management LP (1.44%), Maple Rock Capital Partners Inc. (0.92%), River Road Asset Management LLC (0.45%), Alberta Investment Management Corp (0.39%) and Laurion Capital Management LP (0.29%). How do I buy shares of Bausch + Lomb? Shares of BLCO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NYSE:BLCO) was last updated on 12/8/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bausch + Lomb Co. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.